{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-057398","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2025-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.077763+00:00","generated_at":"2026-05-23T08:21:39.175042+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Candel Therapeutics announces oral presentation of positive Phase 3 CAN-2409 data in prostate cancer at ASCO 2025","bullets":["Phase 3 CAN-2409 data in localized prostate cancer accepted for oral presentation at ASCO 2025 (May 30-June 3, Chicago).","Presenter is Theodore DeWeese, M.D., Dean and CEO of Johns Hopkins Medicine.","Full abstracts released by ASCO on May 22, 2025 at 5:00 PM ET.","Candel will post presentation details on its website after the event."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-057398","json":"https://secwatch.observer/filing/0000950170-25-057398.json","markdown":"https://secwatch.observer/filing/0000950170-25-057398.md","text":"https://secwatch.observer/filing/0000950170-25-057398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025057398/0000950170-25-057398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025057398/cadl-20250423.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T08:21:39.175042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}